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There is a very high prevalence of basal cell carcinoma 
(BCC) in north Queensland,1 and general practitioners 
play an important role in BCC management.2 Each of 
the BCC histological subtypes, body sites, and growth 
patterns have different risks.3 
General practitioners can use a range of treatments 
appropriate for the histological variant.4 Surgical excision 
is an appropriate treatment for all BCC, but not the only 
appropriate treatment.5–7 Double freeze thaw cryotherapy 
and shave curettage/cautery are also effective for some 
superficial BCC (SBCC),8 as are topical imiquimod 5% 
cream (an immune response modifier5), and photodynamic 
therapy (PDT) (topical photosensitising agent plus red 
spectrum light activation8,9). However, there is little data 
on how GPs select from these options.10 
Method
The study’s design was a cross sectional survey. A self 
administered questionnaire (with introductory letter and 
return addressed envelope) was sent to 107 of 257 GPs 
identified from databases of one rural and one provincial 
division in north Queensland (of whom 76 were either no 
longer present or no longer a GP) between May and July 
2005. Participants could reply by the return addressed 
envelope supplied, or by fax. Nonrespondents were sent 
a reminder after 4 weeks.
Questionnaire
The questionnaire was seven pages long with 28 items, 
including demographic questions modelled on the 
Bettering the Evaluation and Care of Health (BEACH) 
report.11 Only demographic data were collected from GPs 
who self reported they typically treated less than two 
SBCC per month. Those who treated two or more per 
month were asked about their current management. Each 
SBCC could be counted for as many treatment options 
as the GP recorded. The questionnaire also asked about 
alternatives to surgery when this was less appropriate 
for reasons of age, co-existing medical conditions, 
medication, or patient preference, or when the GP’s 
level of surgical skill or confidence was low.5 Finally, 
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the questionnaire asked how management 
would change if some topical applications 
were subsidised through the Pharmaceutical 
Benefits Scheme (PBS). 
Statistical analysis
Statistical analysis dichotomised the number 
of primary SBCC lesions treated in a month 
and report numerical variables as medians 
and interquartile ranges (IQR)). The bivariate 
re la t ionsh ips between the dependent 
variable and the GPs’ demographic data 
were assessed by means of chi-square tests 
and nonparametric Wilcoxon and Kruskal Wallis 
tests, as appropriate. Significance was set 
at <0.05.
 Ethical approval for this study was obtained 




The total response was 107 (59%) (56% 
of urban GPs, and 66% of rural). Nearly 
half (49%) of respondents were women. 
Most respondents:
• were aged 35–54 years (70%) 
•  graduated in Australia (67%)
•  had postgraduate genera l  pract ice 
qualifications (74%)
•  had been in practice >10 years (65%)
• were currently working full time (62%), 
and 
•  considered themselves a ‘regular’ GP (ie. 
not working in a hospital or skin cancer 
clinic) (70%), although 43% reported not 
working in a private general practice.
Compared with BEACH data, respondents 
were significantly more likely to:
•  be younger (p=<0.001)
• be women (p=<0.001)
•  have been in practice longer (p=<0.012)
•  have Fellowship of The Royal Australian 
College of General Practitioners (FRACGP) 
(p=<0.001), and
•  work in group practices (p=<0.022).11 
Current management of SBCC 
Sixty-six (62%) GPs treated two or more SBCC 
each month. The most common self reported 
method of treatment for newly diagnosed 
primary SBCC in the past 12 months was 
surgery (56%) followed by imiquimod 5% 
cream (19%) (Figure 1). Most GPs (80%) would 
only treat 1–2 SBCC at one time per patient, 
although some (8%) said they would do so for 
four or more. If monitoring, the median time 
GPs would wait between treatments was 4 
weeks (IQR 0–8 weeks).
Reasons for referral
General practitioners treated a median of 90% 
(IQR 90–99%) SBCC themselves. Referrals 
were most likely to be to plastic surgeons 
(40%; IQR 10–50%), other surgeons (10%; 
IQR 0–50%),  o r  dermato log is ts  (5%; 
IQR 0–40%). Very few referrals were to 
hospitals or skin cancer clinics. Main reasons for 
referral were:
• problematic body sites (60%; IQR 50–
83%)
• large lesions (15%; IQR 0–30%), and 
• patient request (10%, IQR 0–10%). 
Less common reasons cited included lacking 
equipment, or skills (Table 1). 
Use and adequacy of different treatment 
modalities 
Recurrence rates and inadequate primary 
excision after surgery were estimated as 
5% of lesions by 52% of GPs, 6–10% by 
34%, and 11–20% by 14%. Some (77%) 




























Figure 1. Self reported management of SBCC in the past year
Table 1. Contraindications to treatments for SBCC
   %
    Curettage  
  Surgical  and/or Imiquimod 
 excision Cryotherapy cautery 5% cream PDT
 n=65 n=63 n=64 n=65 n=65
Nil 48 32 34 20 28
Don’t know 5 5 14 14 43
Patient factors* 19 15 9 43 20
Doctor factors  2 13 11 8 2 
(eg. inexperience, lack of skill,  
uncertainty of diagnosis) 
Lesion factors (eg. site, size, 28 41. 32 16 9  
infection, scarring) 
* Contraindications, nominated by GPs, included: 
• general (preference, frailty, medication, litigious, history of melanoma), and 
•  specific to imiquimod 5% cream (previous adverse reaction, allergy, scarring, immune 
suppression, pregnancy, unable to follow instructions)
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used curettage or cautery. Estimates of further 
treatment required after cryotherapy were 0–
10% of lesions by 45% of GPs, 11–20% by 
32%, and >20% by 23%of GPs. Of the 27 GPs 
who used curettage and cautery, 30% estimated 
10% or more lesions required further treatment. 
Liquid nitrogen was used for most cryotherapy. 
Self reported management of SBCC where 
primary treatment failed is outlined in Table 2.
 General practitioners considered surgery 
would not be their first line treatment in 40% 
(IQR 10–70%) of SBCC. Most (90%) (IQR 
80–100%) reported they would init iate 
treatment with imiquimod themselves. 
Half  (50%) ( IQR 0–100%) would refer 
to a dermatologist for photodynamic therapy 
(PDT).  Few (6%) reported they never 
biopsied, 38% sometimes, 27% mostly, and 
29% always.
 Many  repo r ted  the i r  management 
would change if topical imiquimod were 
subsidised (Table 3). 
Discussion
The study had limitations. Respondents may 
not have been representative (data were 
significantly different from those from the 
general GP population in the BEACH report,11 
although no different from those from the 
provincial division of general practice in 
199812). Moreover, these data report neither 
actual practice or clinical diagnostic accuracy 
– the doctors’ behaviour might differ to 
that reported. Recall bias is one potential 
reason for this.
 It was unexpected that few GPs reported 
treating more than two SBCC per month in an 
area of high skin cancer incidence. This uneven 
delivery of care in general practice for skin 
cancer has been previously reported.2
 Self reporting by GPs regarding treatment 
of one of the most common skin cancers 
confirms previous data from the same region,2,13 
providing validity to these data. As expected, 
the most common management for SBCC 
was surgery. 
 The  Na t i ona l  Hea l th  and  Med ica l 
Research Council nonmelanoma skin cancer 
management guidelines differentiate between 
management of primary and recurrent BCC, 
as recurrent lesions recur at least 50% 
more often than nonrecurrent lesions,8 
and best management of inadequately 
excised or close to margin tumours remains 
controversia l .3,8,14 This study’s data on 
reported management options for recurrent 
SBCC demonstrated a range of approaches, 
some probably suboptimal, highl ighting 
education needs.5
 A clearer definition is needed, in the form of 
evidence and guidelines, of where surgery is 
less appropriate in management of SBCC, and 
topical applications (eg. imiquimod 5% cream 
and PDT) more.
Implications for general practice
What we already know:
•  Appropriate GP management of most 
SBCC is surgical.
What this study shows:
•  General practitioners consider surgery 
inappropriate in 40% of SBCC.
•  Top ica l  t reatment  moda l i t ies  (eg . 
imiquimod 5% cream and PDT) would 
Table 3. Predicted change in usage of topical applications for treatment  
of SBCC if subsidised through PBS 
Modality of treatment  %
 Unsubsidised* Subsidised* 
 (n=58) (n=61) p value
Cryotherapy double freeze 34.3 15.8 <0.001
Cryotherapy single freeze 8.2 4.5 NS
curettage and/or cautery 6.6 4.5 NS 
Imiquimod 5% cream 34.4 57.9 <0.001
Photosensitising agent plus PDT 5.9 9.6 NS
Noninterventional monitoring 2.5 1.9 NS
Other 8.8 5.2 NS
* Some data missing
Table 2. Treatments for recurring SBCC treated previously with surgery, cryotherapy, 
curettage and cautery, or topical applications
Management options           % treated previously by: 
for recurrent SBCC Surgery Cryotherapy Curettage Topical
 (n=65) (n=53) and/or  applications 
   cautery (n=63) 
   (n=25)
Surgery 59 66 56 67
Cryotherapy – 11 8 2
Curettage and/or cautery 3 4 – 2
Imiquimod 5% cream 12 4 4 6
Refer patient 11 – – 8
Biopsy plus imiquimod 5% cream – – 4 –
Surgery plus curettage/cautery – 2 12 2
Surgery plus imiquimod 5% cream 8 13 8 6
Cryotherapy plus imiquimod  
5% cream 3 – 4 2
Curettage and/or cautery plus  
imiquimod 5% cream – – 4 –
Radiotherapy 2 – – 2
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be used more often by GPs if subsidised 
through the PBS.
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How to be Old in a Hospital Bed 
Your clothes are at least musty, if not positively grubby, if you have any
if you have a relative to bring them in, you have no friends
who are able to come, if they aren’t dead they can’t drive
or are in a nursing home or hostel or they’ve lost their Elgins.
If you have sons and daughters who visit, their grandkids’ll complain
then run off to play with the wheelchairs and be yelled at by the nurses.
Then you must choose your disease, there’s a comprehensive list
but one thing’s for sure, at your age you’ve got pain
arthritis, cracked back bone, whatever, they’ll give you Paracetamol
and you’re not allowed to smoke or drink
(getting shickered is out of the question, even on Christmas Day)
the only taste you have left is for sweet things
chocolates, jubes and desserts, but if you’re diabetic, bad luck
and anyway you might cop a ‘Swallowing Deficit’ diagnosis
from the speech pathologist so all your meat’s mashed up
and your drinks closely resemble custard
you’ll sleep sixteen hours a day because you no longer drift deeply
(and therefore you no longer dream) you’ll doze in a chair
and they’ll say you are lazy or lack motivation
you’ll be treated like a child even if you can do a crossword
with your tongue tied in the back of your throat
which it could be, by various things. Parkinson’s does a neat job
and trusses your limbs up as well.
    So
here you are, waiting for something to happen
but it never does, not quickly, ninety year-old bones
can take six months to heal and sometimes they don’t
they won’t operate, even a skin cancer’s out of the question
you’d be smothered by the anaesthetic
which would suit you just fine, you’ll find yourself thinking
after being here less than a day.
John West
Poetry
We glide through this poem on a prosodic wheelchair, that groans with 
the weight of our aging bodies, and stops at our bed as we become 
exhausted. The poet’s empathy knows more than shared contentment: it 
identifies profoundly with all emotions, including the one that closes this 
neat conversational piece.
Tim Metcalf
